UPDATE: BioMimetic Therapeutics (BMTI) Sees Upside on Stronger Volume
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Join SI Premium – FREE
(Updated - June 22, 2012 11:12 AM EDT)
BioMimetic Therapeutics (Nasdaq: BMTI) vlatility is up 8.6 percet as shares run 15 percent higher early on the day.
Shares are getting above their 200-day DMA of $2.67.
This is the highest shares have been since last October.
UPDATE - Shares are moving following positive news Thursday that its Augment Injectable Bone Graft (AIBG) met its primary endpoint of non-inferiority of AIBG to autograft as assessed by CT scan at six months.
For more color, click here.
BioMimetic Therapeutics (Nasdaq: BMTI) vlatility is up 8.6 percet as shares run 15 percent higher early on the day.
Shares are getting above their 200-day DMA of $2.67.
This is the highest shares have been since last October.
UPDATE - Shares are moving following positive news Thursday that its Augment Injectable Bone Graft (AIBG) met its primary endpoint of non-inferiority of AIBG to autograft as assessed by CT scan at six months.
For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lumentum's optical components sold out through early 2029: CEO
- Musk rules out TSMC role in Terafab operations; Intel gains
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
